Ianalumab Faces a Harder Approval Path in Sjögren’s Disease
Findings from two nearly identical randomized trials have made the case for ianalumab less straightforward than it first appeared. The anti-B-cell biologic, developed for Sjögren’s disease, had already drawn attention because both studies met their primary endpoint of improving disease activity more than placebo. New publication, however, puts that signal under a brighter light and makes clear how fragile a regulatory argument can become when each individual trial sits close to the line.
The two studies, NEPTUNUS-1 and NEPTUNUS-2, were designed in parallel and shared the same basic framework. Each tested whether treatment with ianalumab produced a greater change from baseline in disease activity than placebo. That primary endpoint was reached in both trials, but the margins were thin enough that the results had already invited caution when presented at the American College of Rheumatology meeting last year. Publication has now sharpened that caution rather than easing it.
In diseases like Sjögren’s, where immune activation drives chronic glandular injury and systemic symptoms, B-cell targeting remains biologically plausible. B cells help sustain autoantibody production and inflammatory signaling, so blocking them can reduce the immune cascade that keeps the disease active. The question is not whether the mechanism makes sense. The question is whether the measured clinical benefit is large, consistent, and durable enough to justify approval in a condition that remains difficult to treat and even harder to measure cleanly.
The appeal of ianalumab lies in that biology. Sjögren’s disease is not a disorder with one simple symptom or one clean biomarker. Patients can live with dryness, fatigue, pain, and broader extraglandular manifestations, and the mismatch between what is felt at the bedside and what can be captured on a trial instrument has long complicated drug development. A treatment can move an endpoint without resolving the daily burden of the disease, and a small numerical gain can look more impressive in a pooled analysis than it does when each trial is viewed on its own.
The original conference presentation suggested both NEPTUNUS studies had crossed the finish line on their primary endpoint, but the p values were close to the conventional 0.05 boundary. That is the kind of result that can support optimism in a slide deck and still leave room for regulatory doubt. Pooling the data made the efficacy signal appear stronger, yet pooled analyses can also conceal the unevenness of individual trial performance. When a program depends on two nearly matching studies and each one barely succeeds, the strength of the case rests not on spectacle but on reproducibility.
Why Sjögren’s Trials Are So Difficult to Interpret
The disease itself is part of the problem. Sjögren’s disease has a heterogeneous clinical course, and response assessment often depends on composite measures or symptom scales that can be influenced by factors outside the underlying immune process. Dryness can fluctuate. Fatigue can be shaped by sleep, mood, pain, and other comorbidities. Even when a biologic changes immunologic activity, the patient may not experience a proportionate shift in how she or he feels day to day. That disconnect can blunt the apparent clinical value of an otherwise rational therapy.
Placebo-controlled autoimmune trials also tend to expose how much room there is for regression to the mean, expectation effects, and noise in symptom reporting. In a condition as variable as Sjögren’s, a modest difference between active drug and placebo can look meaningful statistically while remaining uncertain clinically. Regulators often have to decide whether the endpoint reflects a true disease-modifying effect or a narrow gain that may not translate into broad patient benefit.
Ianalumab now sits squarely in that gray zone. Meeting the primary endpoint in both NEPTUNUS trials keeps the program alive, but close results can still be read as vulnerable rather than decisive. A compound that approaches significance in separate trials may still fail to inspire confidence if the magnitude of benefit is small, the consistency is imperfect, or the clinical relevance of the endpoint remains open to debate. In autoimmune drug development, those distinctions are not academic; they determine whether a product moves toward labeling, further study, or an apparent dead end.
The publication also changes the tone around the program. Conference data can sustain momentum, especially when a pooled analysis looks stronger than either study alone. Publication usually forces a more rigorous accounting of the same numbers, and in this case the rigorous account appears less forgiving. The regulatory pathway no longer looks like a simple extension of an encouraging presentation. It now looks like a sequence of increasingly difficult questions about effect size, endpoint meaning, and whether the totality of evidence is convincing enough for approval.
For patients and clinicians, the practical consequence is delay, uncertainty, and continued reliance on limited treatment options. Sjögren’s remains a disease with a substantial unmet need, and any therapy that can genuinely suppress the immune machinery behind it would matter. But a biologic aimed at B-cell activity has to do more than make a statistical point. It has to show that the immune signal it changes is the same one driving the burden patients carry into the clinic.
The published NEPTUNUS results do not close the door on ianalumab. They make the door narrower. A regulatory decision will likely depend on how much confidence can be placed in two borderline trials, how the pooled evidence is weighed against the individual studies, and whether the observed changes in disease activity are persuasive enough to justify a new option in a disorder that still lacks clearly effective therapy.